184 related articles for article (PubMed ID: 8813470)
1. Somatostatin receptor imaging: predictive and prognostic considerations.
Anthony LB; Martin W; Delbeke D; Sandler M
Digestion; 1996; 57 Suppl 1():50-3. PubMed ID: 8813470
[TBL] [Abstract][Full Text] [Related]
2. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
3. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
Janson ET; Westlin JE; Eriksson B; Ahlström H; Nilsson S; Oberg K
Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
[TBL] [Abstract][Full Text] [Related]
4. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
Gotthardt M; Béhé MP; Grass J; Bauhofer A; Rinke A; Schipper ML; Kalinowski M; Arnold R; Oyen WJ; Behr TM
Endocr Relat Cancer; 2006 Dec; 13(4):1203-11. PubMed ID: 17158765
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
7. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H
Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
[TBL] [Abstract][Full Text] [Related]
9. 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours.
Hashemi SH; Benjegård SA; Ahlman H; Wängberg B; Forssell-Aronsson E; Billig H; Nilsson O
Br J Surg; 2003 May; 90(5):549-54. PubMed ID: 12734860
[TBL] [Abstract][Full Text] [Related]
10. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
11. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.
Wängberg B; Westberg G; Tylén U; Tisell L; Jansson S; Nilsson O; Johansson V; Scherstén T; Ahlman H
World J Surg; 1996 Sep; 20(7):892-9; discussion 899. PubMed ID: 8678968
[TBL] [Abstract][Full Text] [Related]
12. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide.
Forssell-Aronsson E; Fjälling M; Nilsson O; Tisell LE; Wängberg B; Ahlman H
J Nucl Med; 1995 Jan; 36(1):7-12. PubMed ID: 7799086
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors.
Janson ET; Kälkner KM; Eriksson B; Westlin JE; Oberg K
Nucl Med Biol; 1999 Nov; 26(8):877-82. PubMed ID: 10708300
[TBL] [Abstract][Full Text] [Related]
15. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
16. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).
Olsen JO; Pozderac RV; Hinkle G; Hill T; O'Dorisio TM; Schirmer WJ; Ellison EC; O'Dorisio MS
Semin Nucl Med; 1995 Jul; 25(3):251-61. PubMed ID: 7570044
[TBL] [Abstract][Full Text] [Related]
18. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
19. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor imaging in patients with neuroendocrine tumors: preoperative and postoperative scintigraphy and intraoperative use of a scintillation detector.
Ahlman H; Tisell LE; Wängberg B; Nilsson O; Forssell-Aronsson E; Fjälling M
Semin Oncol; 1994 Oct; 21(5 Suppl 13):21-8. PubMed ID: 7992076
[No Abstract] [Full Text] [Related]
[Next] [New Search]
